State Ledger
Company profile

Xilio Therapeutics, Inc. CIK 1840233

Ticker
XLO (Nasdaq)
Industry
Pharmaceutical Preparations
Headquarters
Waltham, MA 02451
Fiscal year end
2025 (FY)
Market Data
Close
$8.97
Change
-$0.45
Change %
-4.78%
Volume
412

XLO · trading date Oct 13, 2026 · previous close $9.42 · source: Alpaca (IEX feed, not consolidated full-market data).

Key Financials
Revenue
$43.77M
Net income
-$35.04M
Total assets
$154.69M
Total liabilities
$119.41M
Stockholders' equity
$35.27M
Cash & equivalents
$137.53M
Operating income
-$41.98M
Operating cash flow
-$4.99M
Capital expenditures
$518.0K

Fiscal year 2025, via 10-K filed 2026-03-23. A dash means this figure wasn't reported in the source filing under a field State Ledger recognizes - not that the value is zero.

Financial Performance
Operating margin
-95.9%
Net margin
-80.1%
Free cash flow
-$5.51M
Free cash flow margin
-12.6%
Liabilities / assets
77.2%
Equity / assets
22.8%
CapEx / revenue
1.2%
Operating cash flow / net income
0.14×

Derived from the fiscal year 2025 figures above. These metrics are mathematical calculations and do not represent a rating or assessment of the company.

Financial History
Fiscal yearRevenueNet incomeAssetsLiabilitiesEquity
2025 $43.77M -$35.04M $154.69M $119.41M $35.27M
2024 $6.34M -$58.24M $71.08M $53.48M $17.60M
2023 — -$76.40M $60.93M $24.10M $36.83M
2022 — -$88.22M $139.17M $33.52M $105.65M
2021 — -$75.80M $218.06M $32.63M $185.43M
Company Details
SIC code
2834
State of incorporation
DE
Active filer
Yes
Most recent SEC filing
Form SCHEDULE 13G/A
2026-08-14
Financials filed via
Form 10-K
filed 2026-03-23

"Most recent SEC filing" may differ from the filing used for the financial figures above.

Location
Waltham, MA 02451
828 WINTER STREET
Data & Methodology

SEC EDGAR submissions API (identity, collected Sep 19, 2026, 15:11 UTC) and SEC XBRL Company Facts API (financials, collected Sep 26, 2026, 15:35 UTC) · figures as originally filed, not restated · a dash always means a value wasn't reported, never a real zero.

← Back to Massachusetts — Public Companies